MCID: HYP069
MIFTS: 57

Hyperparathyroidism

Categories: Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Hyperparathyroidism

MalaCards integrated aliases for Hyperparathyroidism:

Name: Hyperparathyroidism 12 29 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:13543
ICD10 33 E21.3
ICD9CM 35 252.0 252.00
MeSH 42 D006961
NCIt 47 C48259
UMLS 69 C0020502

Summaries for Hyperparathyroidism

Disease Ontology : 12 A parathyroid gland disease characterized by an overactivity of the parathyroid glands, leading to an excess of parathyroid hormone in the body.

MalaCards based summary : Hyperparathyroidism is related to hyperparathyroidism 3 and hyperparathyroidism-jaw tumor syndrome. An important gene associated with Hyperparathyroidism is CASR (Calcium Sensing Receptor), and among its related pathways/superpathways are Development_Hedgehog and PTH signaling pathways in bone and cartilage development and Transcription_Role of VDR in regulation of genes involved in osteoporosis. The drugs Benzocaine and Sevelamer have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and thyroid, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 72 Hyperparathyroidism is an increased parathyroid hormone (PTH) levels in the blood. This occurs either... more...

Related Diseases for Hyperparathyroidism

Diseases in the Hyperparathyroidism family:

Hyperparathyroidism, Familial Primary Hyperparathyroidism 3
Hyperparathyroidism 4

Diseases related to Hyperparathyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 342)
id Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 3 34.6 CDC73 GCM2 MEN1
2 hyperparathyroidism-jaw tumor syndrome 34.6 CASR CDC73 MEN1 RET
3 hyperparathyroidism 4 33.9 GCM2 PTH
4 parathyroid carcinoma 32.4 CALCA CASR CDC73 MEN1 PTH
5 multiple endocrine neoplasia iib 31.4 CALCA CDC73 MEN1 PTH RET
6 parathyroid gland disease 30.3 BGLAP CASR FGF23 GCM2 PTH PTHLH
7 pheochromocytoma 30.2 CALCA CHGA MEN1 RET
8 calcinosis 30.1 EPO FGF23 PTH
9 hyperparathyroidism, familial primary 27.7 ACP5 BGLAP CALCA CASR CDC73 CDKN1B
10 hyperparathyroidism, neonatal 12.3
11 secondary hyperparathyroidism of renal origin 12.1
12 nephropathy, deafness, and hyperparathyroidism 12.0
13 hypophosphatemic rickets and hyperparathyroidism 12.0
14 hyperparathyroidism, primary, caused by water clear cell hyperplasia 11.8
15 non-renal secondary hyperparathyroidism 11.7
16 cdc73-related familial isolated hyperparathyroidism 11.7
17 osteitis fibrosa 11.6
18 parathyroid adenoma 11.3
19 multiple endocrine neoplasia 1 11.2
20 nephrocalcinosis 11.2
21 familial hypocalciuric hypercalcemia 11.1
22 rickets 11.1
23 multiple endocrine neoplasia iia 10.9
24 childhood intracortical osteosarcoma 10.9 MEN1 PTH
25 achondrogenesis 10.8 BGLAP PTH
26 methylmalonic acidemia due to transcobalamin receptor defect 10.7 CASR CDC73 PTH
27 basilar impression, primary 10.7
28 osteopetrosis, autosomal recessive 1 10.7
29 rickets, vitamin d-resistant, type iia 10.7
30 vitamin d-dependent rickets, type i 10.7
31 chondrocalcinosis 2 10.7
32 cardiovascular organ benign neoplasm 10.7 CDC73 MEN1 PTH
33 pemphigus foliaceus 10.6 CALCA MEN1
34 histiocytoid hemangioma 10.6 CASR FGF23 VDR
35 central hypoventilation syndrome, congenital 10.6 CALCA MEN1 RET
36 prediabetes syndrome 10.6 BGLAP FGF23 PTH
37 tibial hemimelia 10.6 CALCA TNFRSF11B
38 bullous impetigo 10.6 CASR PRKAR1A
39 hypophosphatasia, adult 10.6 BGLAP CALCA PTH
40 hypochondrogenesis 10.5 CALCA PTH TNFRSF11B
41 brain angioma 10.5 MEN1 PTH PTHLH
42 teratocarcinoma 10.5 PTH PTHLH
43 spinocerebellar ataxia 4 10.5 BGLAP FGF23 TNFRSF11B
44 photoallergic dermatitis 10.5 BGLAP PTH PTHLH
45 pinched nerve 10.5 FGF23 PTHLH
46 carcinoma of unknown primary site, childhood 10.5 CALCA CHGA MEN1
47 obesity, severe bmiq9 10.5 BGLAP PTH PTHLH
48 hypocalcemia, autosomal dominant 10.5 CASR PRKAR1A
49 cerebrooculofacioskeletal syndrome 4 10.4 CASR PTHLH
50 restless legs syndrome 1 10.4 CYP27B1 VDR

Comorbidity relations with Hyperparathyroidism via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Kidney Failure
Deficiency Anemia Hypertension, Essential
Hypoparathyroidism Hypothyroidism
Nephrolithiasis, Type I Osteoporosis
Parathyroid Carcinoma

Graphical network of the top 20 diseases related to Hyperparathyroidism:



Diseases related to Hyperparathyroidism

Symptoms & Phenotypes for Hyperparathyroidism

MGI Mouse Phenotypes related to Hyperparathyroidism:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 CDC73 CDKN1B CHGA CYP27B1 EPO FGF23
2 homeostasis/metabolism MP:0005376 10.38 RET VDR CASR CDC73 CDKN1B CHGA
3 cellular MP:0005384 10.37 MEN1 PHEX PRKAR1A PTHLH RET TNFRSF11B
4 endocrine/exocrine gland MP:0005379 10.37 CYP27B1 FGF23 GAST GCM2 MEN1 PRKAR1A
5 growth/size/body region MP:0005378 10.36 CASR CDC73 CDKN1B CHGA CYP27B1 FGF23
6 immune system MP:0005387 10.33 MEN1 PHEX PRKAR1A PTH PTHLH RET
7 hematopoietic system MP:0005397 10.31 EPO FGF23 PHEX PRKAR1A PTH PTHLH
8 digestive/alimentary MP:0005381 10.28 CASR CDC73 CDKN1B FGF23 GAST MEN1
9 mortality/aging MP:0010768 10.27 RET TNFRSF11B VDR CASR CDC73 CDKN1B
10 craniofacial MP:0005382 10.25 CDKN1B CYP27B1 GCM2 MEN1 PHEX PRKAR1A
11 limbs/digits/tail MP:0005371 10.06 CYP27B1 EPO FGF23 PHEX PTH PTHLH
12 adipose tissue MP:0005375 10.05 CDC73 CDKN1B CYP27B1 PHEX PRKAR1A PTHLH
13 integument MP:0010771 10.03 CYP27B1 EPO FGF23 PTHLH VDR CASR
14 renal/urinary system MP:0005367 10 CASR CDC73 CDKN1B CHGA CYP27B1 FGF23
15 muscle MP:0005369 9.92 CASR CDC73 CDKN1B EPO MEN1 PRKAR1A
16 reproductive system MP:0005389 9.85 CDC73 CDKN1B CHGA CYP27B1 FGF23 MEN1
17 respiratory system MP:0005388 9.5 CDC73 CDKN1B EPO FGF23 PRKAR1A PTHLH
18 skeleton MP:0005390 9.4 PHEX PRKAR1A PTH PTHLH TNFRSF11B VDR

Drugs & Therapeutics for Hyperparathyroidism

Drugs for Hyperparathyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
2
Sevelamer Approved Phase 4,Phase 3,Phase 2 52757-95-6, 152751-57-0 3085017
3
Calcium acetate Approved Phase 4,Phase 3 62-54-4
4
Denosumab Approved Phase 4,Phase 3,Phase 1 615258-40-7
5
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
6 Strontium ranelate Approved Phase 4 135459-87-9
7
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
8
Calcium Carbonate Approved Phase 4,Phase 3,Phase 2 471-34-1
9
Zoledronic acid Approved Phase 4,Phase 1 118072-93-8 68740
10
Pamidronate Approved Phase 4 40391-99-9 4674
11
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
12 Racepinephrine Approved Phase 4
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Iron Approved Phase 4 7439-89-6 23925
15
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-14-6 5280793
16 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1406-16-2
18
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1 67-97-0 6221 10883523 5280795
19
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 32222-06-3 134070 5280453
20
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2 41294-56-8 5282181
21
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
23
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
24
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
25
Angiotensin II Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
26 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1
30 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1
38 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Hydroxycholecalciferols Phase 4,Phase 3,Phase 2
40 Calcifediol Phase 4,Phase 3,Phase 1 19356-17-3
41 Antimetabolites Phase 4,Phase 2,Phase 1
42 Hypolipidemic Agents Phase 4,Phase 2
43 Lipid Regulating Agents Phase 4,Phase 2
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
45 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
46 Epoetin alfa Phase 4 113427-24-0
47 Hematinics Phase 4
48 Anticholesteremic Agents Phase 4
49 Atorvastatin Calcium Phase 4 134523-03-8
50 Chelating Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 320)

id Name Status NCT ID Phase Drugs
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
3 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
4 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
5 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
6 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4 Denosumab
7 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4 AMG 073
8 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
9 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
10 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
11 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
12 Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
13 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
14 Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
15 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
16 Evaluation of a Cincalcet Suppression Test Completed NCT01103206 Phase 4 cinacalcet;cinacalcet dose 1;cinacalcet dose 2
17 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
18 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
19 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
20 Vitamin D Repletion in Primary Hyperparathyroidism Completed NCT01306656 Phase 4 10,000 IU Vitamin D3
21 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
22 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
23 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
24 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
25 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
26 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
27 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
28 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
29 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
30 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Completed NCT02056730 Phase 4 calcium sensing receptor agonist
31 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
32 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
33 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4 doxercalciferol
34 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
35 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4 Cinacalcet
36 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
37 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
38 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
39 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
40 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4 cinacalcet
41 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
42 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
43 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
44 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
45 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
46 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol
47 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
48 Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation Completed NCT02249741 Phase 4 Treated with Ibandronic acid as per protocol
49 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
50 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet

Search NIH Clinical Center for Hyperparathyroidism

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hyperparathyroidism

Genetic Tests for Hyperparathyroidism

Genetic tests related to Hyperparathyroidism:

id Genetic test Affiliating Genes
1 Hyperparathyroidism 29

Anatomical Context for Hyperparathyroidism

MalaCards organs/tissues related to Hyperparathyroidism:

39
Kidney, Bone, Thyroid, Testes, Endothelial, Liver, Heart

Publications for Hyperparathyroidism

Articles related to Hyperparathyroidism:

(show top 50) (show all 2000)
id Title Authors Year
1
Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial. ( 28918310 )
2017
2
Bipolar Disorder With Mixed Features Associated With Primary Hyperparathyroidism. ( 28010754 )
2017
3
Brown tumor: clinical findings of secondary hyperparathyroidism in patients with renal osteodystrophy. ( 28253186 )
2017
4
Hyperparathyroidism. ( 28923463 )
2017
5
Ultrasound-based scores as predictors for nodular hyperplasia in patients with secondary hyperparathyroidism: a prospective validation study. ( 28054194 )
2017
6
Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism. ( 28900835 )
2017
7
Gender difference in the clinical presentation of primary hyperparathyroidism: Influence of menopausal status. ( 28938410 )
2017
8
Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. ( 27858283 )
2017
9
A HISTOPATHOLOGICAL AUDIT OF HYPERPARATHYROIDISM IN THE SOUTH AFRICAN SETTING. ( 28876685 )
2017
10
Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. ( 28674121 )
2017
11
Effect of parathyroidectomy on osteopontin and undercarboxylated osteocalcin in patients with primary hyperparathyroidism. ( 28937873 )
2017
12
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1I+,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ( 28905271 )
2017
13
FREE AND BIOAVAILABLE 25-HYDROXYVITAMIN D LEVELS IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM. ( 27682354 )
2017
14
Surgery Significantly Improves Neurocognition, Sleep, and Blood Pressure in Primary Hyperparathyroidism: A 3-Year Prospective Follow-Up Study. ( 28922677 )
2017
15
Primary hyperparathyroidism: Dynamic postoperative metabolic changes. ( 28906021 )
2017
16
High Incidence of Secondary Hyperparathyroidism in Bariatric Patients: Comparing Different Procedures. ( 28921422 )
2017
17
Nontraumatic Multiple Vertebral Compression Fractures Induced by Primary Hyperparathyroidism: A Case Report and Literature Review. ( 28882718 )
2017
18
Water Clear Cell Adenoma of the Parathyroid Gland: A Forgotten Cause of Primary Hyperparathyroidism. ( 28382826 )
2017
19
Association of ADAMTS4 and ADAMTS9 levels with cardiovascular risk in patients with primary hyperparathyroidism. ( 28937860 )
2017
20
Primary hyperparathyroidism caused by enormous unilateral water-clear cell parathyroid hyperplasia. ( 28888222 )
2017
21
Primary hyperparathyroidism caused by mediastinal ectopic parathyroid adenoma. ( 28775222 )
2017
22
A novel SLC12A1 gene mutation associated with hyperparathyroidism, hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients. ( 28095294 )
2017
23
Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism. ( 27842919 )
2017
24
Successful treatment of early allograft dysfunction with cinacalcet in a patient with nephrocalcinosis caused by severe hyperparathyroidism: a case report. ( 28390426 )
2017
25
Descended right superior parathyroid adenoma mimicking as inferior adenoma in primary hyperparathyroidism. ( 28775111 )
2017
26
Atypical intraosseous meningioma with growth hormone deficiency and hyperparathyroidism after craniospinal irradiation. ( 28948343 )
2017
27
The impact of vitamin D status on hungry bone syndrome after surgery for primary hyperparathyroidism. ( 28877925 )
2017
28
Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1: Reply. ( 27847968 )
2017
29
Simultaneous Incidental Parathyroid Carcinoma and Intrathyroid Parathyroid Gland in Suspected Renal Failure Induced Hyperparathyroidism. ( 28825015 )
2017
30
Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family. ( 28774260 )
2017
31
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitaminA D in Austria and Switzerland - the observational TRANSIT Study. ( 28091752 )
2017
32
Comparative Effectiveness of Ultrasonography, 99mTc-Sestamibi, and 18F-Fluorocholine PET/CT in Detecting Parathyroid Adenomas in Patients With Primary Hyperparathyroidism. ( 28902729 )
2017
33
Pathological fractures in a patient with severe osteomalacia and hyperparathyroidism: a multidisciplinary challenge. ( 28840440 )
2017
34
Hyperparathyroidism caused by distant pulmonary lesions and parathyromatosis after ethanol injection/parathyroidectomy for secondary hyperparathyroidism. ( 28078796 )
2017
35
Acute thyroiditis: An under-recognized complication of parathyroidectomy in end-stage renal failure patients with secondary hyperparathyroidism. ( 28621009 )
2017
36
Parathyroid Carcinoma in Patients that Have Undergone Surgery for Primary Hyperparathyroidism. ( 28882960 )
2017
37
Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ( 28063122 )
2017
38
Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. ( 28073343 )
2017
39
Percentage arterial enhancement: An objective index for accurate identification of parathyroid adenoma/hyperplasia inA primary hyperparathyroidism. ( 28656592 )
2017
40
Primary hyperparathyroidism. ( 28885621 )
2017
41
Papillary carcinoma of the thyroid in patients with primary hyperparathyroidism: Is there a link? ( 28571792 )
2017
42
Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels. ( 27876426 )
2017
43
Management of secondary hyperparathyroidism: how and why? ( 28044233 )
2017
44
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. ( 28057872 )
2017
45
A Case of Hyperparathyroidism due to a Large Intrathyroid Parathyroid Adenoma with Recurrent Episodes of Acute Pancreatitis. ( 28815093 )
2017
46
ANALYSIS OF FACTORS AFFECTING OUTCOME OF ULTRASOUND-GUIDED RADIOFREQUENCY HEAT ABLATION FOR TREATMENT OF PRIMARY HYPERPARATHYROIDISM IN DOGS. ( 27885739 )
2017
47
Exophthalmos and hyperparathyroidism. ( 28750881 )
2017
48
Looking beyond the thyroid: advances in understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms. ( 28874394 )
2017
49
Osteolytic lesions: osteitis fibrosa cystica in the setting of severe primary hyperparathyroidism. ( 28554885 )
2017
50
A case of hypercalcaemic crisis secondary to coexistence of primary hyperparathyroidism and Graves' disease. ( 27941175 )
2016

Variations for Hyperparathyroidism

Expression for Hyperparathyroidism

Search GEO for disease gene expression data for Hyperparathyroidism.

Pathways for Hyperparathyroidism

GO Terms for Hyperparathyroidism

Cellular components related to Hyperparathyroidism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 BGLAP CALCA CHGA EPO FGF23 GAST
2 extracellular space GO:0005615 9.28 BGLAP CALCA CHGA EPO FGF23 GAST

Biological processes related to Hyperparathyroidism according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 BGLAP CDKN1B PTH RET TNFRSF11B
2 negative regulation of cell proliferation GO:0008285 9.95 CDC73 CDKN1B CYP27B1 MEN1 PTHLH VDR
3 response to lipopolysaccharide GO:0032496 9.89 ACP5 CYP27B1 EPO TNFRSF11B
4 negative regulation of epithelial cell proliferation GO:0050680 9.77 CDC73 CDKN1B MEN1
5 positive regulation of cAMP biosynthetic process GO:0030819 9.74 CALCA PTH PTHLH
6 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.73 CALCA PTH PTHLH
7 skeletal system development GO:0001501 9.73 BGLAP PHEX PTH PTHLH TNFRSF11B VDR
8 cellular calcium ion homeostasis GO:0006874 9.72 CALCA CASR GCM2 PTH VDR
9 bone mineralization GO:0030282 9.71 BGLAP CYP27B1 PHEX
10 response to estrogen GO:0043627 9.67 BGLAP CYP27B1 EPO TNFRSF11B
11 positive regulation of ossification GO:0045778 9.65 CALCA PTH
12 response to inorganic substance GO:0010035 9.64 BGLAP TNFRSF11B
13 positive regulation of keratinocyte differentiation GO:0045618 9.64 CYP27B1 VDR
14 response to magnesium ion GO:0032026 9.63 FGF23 TNFRSF11B
15 decidualization GO:0046697 9.63 CYP27B1 MEN1 VDR
16 negative regulation of bone resorption GO:0045779 9.62 CALCA TNFRSF11B
17 vitamin D metabolic process GO:0042359 9.62 CYP27B1 FGF23
18 cellular phosphate ion homeostasis GO:0030643 9.61 FGF23 GCM2
19 cellular response to parathyroid hormone stimulus GO:0071374 9.61 FGF23 PHEX
20 regulation of bone mineralization GO:0030500 9.61 BGLAP CYP27B1 FGF23
21 response to fibroblast growth factor GO:0071774 9.58 CASR PTH
22 negative regulation of calcium ion transport into cytosol GO:0010523 9.58 CALCA EPO
23 osteoblast development GO:0002076 9.58 BGLAP MEN1 PTHLH
24 cAMP metabolic process GO:0046058 9.52 PTH PTHLH
25 response to sodium phosphate GO:1904383 9.51 FGF23 PHEX
26 vitamin D catabolic process GO:0042369 9.49 CYP27B1 FGF23
27 response to vitamin D GO:0033280 9.46 BGLAP CYP27B1 PHEX PTH
28 positive regulation of cAMP metabolic process GO:0030816 9.33 CHGA
29 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.13 CYP27B1 FGF23 VDR
30 cellular response to vitamin D GO:0071305 8.92 BGLAP CASR FGF23 PHEX

Molecular functions related to Hyperparathyroidism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 CALCA EPO GAST PTH PTHLH
2 peptide hormone receptor binding GO:0051428 8.96 PTH PTHLH

Sources for Hyperparathyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....